Alogliptin

Active ingredient description

Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
Discover more medicines within A10BH04

Medicines

Alogliptin is the active ingredient of these drugs:

Drug
Countries

Ecuador

Australia Brazil Canada Hong Kong Singapore

Austria Estonia Finland Ireland Lithuania

Alogliptin is also found within below combination drugs:

FEBUMET , INCRESYNC , KAZANO , NESINA MET , NESINA PIO , OSENI , VIPDOMET

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Structured Product Labeling (SPL/PLR)
US
Summary of Product Characteristics (SPC)

Structural formula

Graphic representation of the active ingredient's molecular structure

Molecular mass: 339.392 g/mol

External identifiers

CAS Substance: 850649-61-5
DrugBank Drug: DB06203
KEGG Drug: D06553
RxNorm Ingredient: 1368001
SNOMED-CT Concept: 702799001
Alogliptin (substance)
UNII Identifier: JHC049LO86
ALOGLIPTIN